Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus

Type 2 diabetes mellitus results in increased risk of fracture and delayed fracture healing. ZDF fa/fa rats are an established model of type 2 diabetes mellitus with low bone mass and delayed bone healing. We tested whether a sclerostin‐neutralizing antibody (Scl‐AbVI) would reverse the skeletal def...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of bone and mineral research 2013-03, Vol.28 (3), p.627-638
Hauptverfasser:	Hamann, Christine, Rauner, Martina, Höhna, Yvonne, Bernhardt, Ricardo, Mettelsiefen, Jan, Goettsch, Claudia, Günther, Klaus‐Peter, Stolina, Marina, Han, Chun‐Ya, Asuncion, Franklin J, Ominsky, Michael S, Hofbauer, Lorenz C
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies - pharmacology Biomechanical Phenomena Blotting, Western Bone and Bones - drug effects Bone and Bones - physiopathology BONE DEFECT Bone Density BONE MASS Bone Morphogenetic Proteins - immunology BONE REGENERATION BONE STRENGTH Diabetes Mellitus, Experimental - physiopathology Diabetes Mellitus, Type 2 - physiopathology Genetic Markers - immunology Male Organ Size - drug effects OSTEOBLAST Rats Regeneration SCLEROSTIN TYPE 2 DIABETES MELLITUS WNT SIGNALING
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!